However, when drugs have been shown to be relatively safe, the bar towards testing them even in long shot trials is worth it and it is, of course, disappointing that this trial has failed
Direct answer: Patients may notice appetite changes, digestive adjustments, and gradual weight changes during the transition period
The beneficial effect of tirzepatide on hsCRP, a biomarker of systemic inflammation, YKL-40, a proinflammatory cytokine, and ICAM-1, a biomarker of endothelial dysfunction, was already detectable at 4 weeks, consistent with the salutary effects of GIP and GLP-1 on inflammation and atherosclerosis in experimental models [84,85,86]
It is administered as a once-weekly subcutaneous injection